Form D · Biotechnology
Auron Therapeutics, Inc.
Wellesley, MA · CIK 0001746139
Offering snapshot reported Aug 13, 2026 · SEC filing
- Reported sold
- $7.12M Offering amount: $12M
- Investors reported
- 14 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Aug 10, 2026 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Aug 13, 2026 | Initial | $7,118,141 | No comparison | 14 | SEC filing |
| Dec 23, 2025 | Amendment | $27,289,180 | $13,894,590vs Dec 31, 2024 | 16 | SEC filing |
| Dec 31, 2024 | Initial | $13,394,590 | No comparison | 15 | SEC filing |
| Oct 20, 2023 | Amendment | $38,399,997 | $12,399,999vs Jul 28, 2022 | 10 | SEC filing |
| Jul 28, 2022 | Initial | $25,999,998 | No comparison | 10 | SEC filing |
| Dec 16, 2020 | Initial | $15,441,157 | No comparison | 25 | SEC filing |
| Jul 25, 2018 | Initial | $660,000 | No comparison | 8 | SEC filing |
Offering details
- Securities
- Debt
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-594148
Source: Form D, filed Aug 13, 2026. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No matching detailed fund disclosure was found in the latest imported ADV filings. This does not establish that the issuer has no adviser.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Alexandra Cantley | Director |
| Isaac Ciechanover | Director |
| Anna French | Director |
| Christopher Guiffre | Executive |
| John Duncan Higgons | Director |
| Alon Lazarus | Director |
| Serge Messerlian | Director |
| Briggs Duncan Morrison | Director |
| Pini Orbach | Director |
| Victoria Richon | Director |
| Eric Shiozaki | Director |
| Katharine Yen | Director, Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
1 Grove Street
Wellesley, MA, 02482-9998
Phone: 310-922-5881
Wellesley, MA, 02482-9998
Phone: 310-922-5881